Polycystic ovary syndrome has long been a common diagnosis for people assigned female at birth who experience irregular periods, excess androgen effects, and metabolic changes. Recently, experts proposed renaming that condition to post-reproductive metabolic ovarian syndrome, abbreviated PMOS. The change emphasizes features that matter most for health across the lifespan, and particularly during menopause. This article explains why the name changed, what the new term highlights, how PMOS is diagnosed, and what women can do to protect their health as they transition through menopause. Practical tips, clinical context, and evidence-based recommendations are included so readers can take immediate, informed steps.
Why was PCOS renamed PMOS?
Maral Malekzadeh, DO, explains that the proposed name PMOS shifts clinical attention from ovarian cysts alone to the lasting metabolic and reproductive effects that persist into and beyond menopause. The old label emphasized ultrasound findings that many people with the condition do not have or that are not the most harmful features. The new name points to two central truths:
The syndrome affects metabolism as well as ovarian function.
Risks linked to the condition, such as insulin resistance, type 2 diabetes, and cardiovascular disease, often continue or emerge after the reproductive years.
Why this matters: Several studies show that women with a history of PCOS have higher rates of metabolic syndrome and type 2 diabetes later in life. For example, a longitudinal cohort found that up to 40 percent of people diagnosed earlier in life had impaired glucose tolerance or diabetes by midlife. The new name encourages clinicians and patients to monitor and treat metabolic health proactively, not only during the childbearing years but also through perimenopause and after menopause.
The benefits of renaming PCOS to PMOS – Clearer risk focus and better long-term care
Renaming the condition offers concrete advantages for patients, clinicians, and public health:
Improves clinical focus. The label PMOS highlights metabolic risk, so screening for insulin resistance, lipid abnormalities, and blood pressure becomes routine.
Reduces confusion. Many people labeled with PCOS felt the name did not reflect their main health concerns. PMOS aligns the label with what drives long-term disease risk.
Guides research and guidelines. A metabolic-first framing can change trial designs and preventive strategies, so outcomes such as cardiovascular disease and diabetes prevention become endpoints.
Encourages lifelong care. The name removes the implication that the condition ends with reproduction and promotes surveillance across decades.
How is PMOS diagnosed? – Practical criteria clinicians use now
Diagnosis remains clinical and multifactorial. Clinicians assess reproductive signs plus metabolic features and exclude other causes. Common components used in practice include:
Clinical or biochemical signs of androgen excess, such as acne, male-pattern hair growth, or elevated serum testosterone.
Menstrual irregularity, including oligomenorrhea or amenorrhea.
Metabolic indicators such as elevated fasting insulin, impaired glucose tolerance, dyslipidemia, or central adiposity.
Doctors also run tests to exclude other conditions with similar findings:
Thyroid disease, hyperprolactinemia, and late-onset congenital adrenal hyperplasia.
Androgen-secreting tumors are associated with very high testosterone levels.
Medications that might cause irregular cycles or weight gain.
Example diagnostic pathway:
History and physical exam focused on menstrual pattern and androgen signs.
Baseline labs: fasting glucose, hemoglobin A1c, fasting lipids, TSH, prolactin, and total testosterone when clinically indicated.
Consider ultrasound for ovarian morphology if questions about reproductive function remain, but recognize that ultrasound is not required for diagnosis.
How menopause impacts PMOS – What changes and what persists
Menopause changes hormone levels dramatically, but PMOS-related metabolic risk often persists and, in some cases, increases. As ovarian estrogen declines, body fat distribution tends to shift toward increased central fat, which magnifies insulin resistance. That effect, when added to pre-existing metabolic vulnerability, elevates risk for:
Type 2 diabetes. Women with prior PCOS/PMOS history show higher midlife rates of diabetes than their peers.
Dyslipidemia and hypertension. Lipid profiles and blood pressure can worsen after menopause.
Cardiovascular disease. Long-term data suggest elevated cardiovascular risk, though absolute risks vary and are modified by lifestyle and medical management.
Menopause also changes reproductive symptoms:
Menstrual irregularity naturally ends with menopause, so cycle-based features lose diagnostic value after the final menstrual period.
Androgenic symptoms such as persistent facial hair or acne may continue and sometimes worsen relative to estrogen decline.
How does PMOS impact menopause symptoms? – What to expect and how symptoms interact
PMOS can alter the experience of menopause in several ways:
Hot flashes and night sweats. Evidence on whether PMOS alters vasomotor symptoms is mixed, but metabolic comorbidities such as obesity correlate with more severe or prolonged vasomotor symptoms in some studies.
Sleep and mood. Insulin resistance and obstructive sleep apnea, both more common in PMOS, contribute to poor sleep and mood disturbances during the menopause transition.
Sexual function. Genitourinary syndrome of menopause causes vaginal dryness and discomfort. Some people with PMOS also report libido changes related to hormonal shifts and metabolic health.
Clinical implications: Managing PMOS during menopause requires attention to both menopausal symptom control and metabolic risk mitigation. Hormone therapy remains an option for vasomotor symptoms for many people, but clinicians weigh benefits and risks carefully in the context of PMOS-related cardiovascular risk.
3 tips for women navigating PMOS and menopause
Prioritize your metabolic health
Monitor. Ask your clinician for regular screening: fasting glucose or hemoglobin A1c yearly or as recommended, lipid panels, and blood pressure checks.
Move and fuel your body. Evidence supports that aerobic and resistance exercise improve insulin sensitivity. A Mediterranean-style diet reduces cardiovascular risk and supports weight management.
Consider medications when indicated. Metformin can help with insulin resistance and is sometimes used. Statins and antihypertensives are prescribed following current guidelines for lipid and blood pressure control.
Don’t ignore new or worsening symptoms
Track changes. Document new hair growth, sudden weight gain, worsening fatigue, chest pain, or shortness of breath, and report them promptly.
Request appropriate tests. New metabolic derangements may require glucose tolerance testing, repeat lipids, or cardiac risk assessment.
Seek specialist care when needed. Endocrinologists, cardiologists, and gynecologists with menopause expertise can help tailor prevention and treatment.
Take care of your mental health, too
Recognize risk. People with PMOS experience higher rates of anxiety and depression, and perimenopause is already a vulnerable period for mood shifts.
Use tools. Cognitive behavioral therapy, support groups, medication when appropriate, and regular physical activity all reduce symptoms.
Build social supports. Peer groups and clear communication with partners and clinicians help manage stress and stigma.
The bottom line on PMOS
Renaming PCOS to PMOS aims to realign clinical priorities toward long-term metabolic health while still acknowledging reproductive features. The new term emphasizes that the condition often persists into midlife and beyond, with important implications for diabetes, cardiovascular disease, and overall quality of life. For women navigating menopause, attentive metabolic screening, lifestyle strategies, symptom monitoring, and mental health care form the backbone of effective management. With proactive care, many of the worst outcomes linked to PMOS are preventable or manageable.
Practical checklist to discuss with your clinician
Annual or more frequent screening for glucose and lipids.
Blood pressure monitoring and cardiovascular risk assessment.
Review of current medications and consideration of metformin or statin therapy when indicated.
Individualized discussion about hormone therapy for menopausal symptoms, weighing benefits and risks.
Referral for mental health support or sleep evaluation if needed.
Also Read | Why Chronic Pain in Women Feels Worse – Harvard Expert Explains Relief
